Association between the CYP2B6 polymorphisms and nonnucleoside reverse transcriptase inhibitors drug-induced liver injury: a systematic review and meta-analysis
Noppadol Chanhom, Janjira Sonjan, Jarupat Inchai, Wanvisa Udomsinprasert, Usa Chaikledkaew, Supharat Suvichapanich, Surakameth Mahasirimongkol, Jiraphun Jittikoon · 2024
Read Association between the CYP2B6 polymorphisms and nonnucleoside reverse transcriptase inhibitors drug-induced liver injury: a systematic review and meta-analysis by Noppadol Chanhom, Janjira Sonjan, Jarupat Inchai, Wanvisa Udomsinprasert, Usa Chaikledkaew, Supharat Suvichapanich, Surakameth Mahasirimongkol, Jiraphun Jittikoon (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11603346.txt.
Description
Noppadol Chanhom and seven colleagues pool the evidence on whether a gene variant raises the risk of liver injury from HIV drugs, in a 2024 meta-analysis. Two widely used drugs, efavirenz and nevirapine, can damage the liver, and a drug-processing gene called CYP2B6 varies between people.
Seventeen genes showed links to the injury, with three processing enzymes sitting at the network's center. Carrying one or two copies of the gene's *6 form roughly doubled the odds of efavirenz-related injury. The same forms, surprisingly, cut nevirapine risk by more than half. The authors say a single gene can push opposite ways depending on the drug, which matters for test-guided prescribing.
Catalog record
| CREATOR | Noppadol Chanhom, Janjira Sonjan, Jarupat Inchai, Wanvisa Udomsinprasert, Usa Chaikledkaew, Supharat Suvichapanich, Surakameth Mahasirimongkol, Jiraphun Jittikoon |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 30 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |